Navigation Links
Abbott Introduces Molecular Diagnostic System Intended for Broad Identification of Infectious Agents
Date:7/21/2009

CHICAGO, July 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today unveiled its new PLEX-ID system currently in development for detecting and characterizing a wide range of pathogens, including infectious agents commonly transmitted in hospitals and other clinical sites. PLEX-ID is the next generation of Abbott's Ibis T5000(TM) Biosensor System and is among an innovative portfolio of instruments and tests the company is featuring this week at the American Association for Clinical Chemistry's 2009 Clinical Lab Expo.

"Research reported in several scientific venues has shown that the Ibis technology could offer applications for the rapid detection of a broad range of microbes, including bacteria, viruses and fungi, in a variety of specimens," said David Ecker, Ph.D., divisional vice president, research and development, Abbott Molecular.

Currently intended to be for research use only, PLEX-ID is a high-throughput technology that simultaneously enables identification and recognition of emerging organisms using a unique combination of both PCR (polymerase chain reaction) and mass spectrometry analysis for detection of microbes.

The system is designed to address a significant unmet clinical need by providing results in six to seven hours instead of three or more days as is required with culturing methods.

"The Ibis technology has demonstrated broad utility in a variety of research applications, including biodefense, forensics, epidemiology and infectious disease surveillance for public health applications," said Stafford O'Kelly, head of Abbott's molecular diagnostics business. "We believe the technology has the potential to be a powerful and versatile tool, particularly for the identification of hospital-borne pathogens."

The PLEX-ID is ex
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Abbott Launches New Instrument to Complete Family of ARCHITECT Immunochemistry Analyzers
2. Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
3. Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal(R) Vet, a New Chemotherapeutic Agent for Dogs
4. Abbott Hosts Conference Call for Second-Quarter Earnings
5. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
6. Schmidt & Clark, LLP: FDA Reports Show Abbott Labs Subsidiary Failed to Disclose Parasite Eye Infections Tied to Contact Lens Solution
7. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
8. Abbott Declares 342nd Consecutive Quarterly Dividend
9. Abbott Announces Launch of Next-Generation Embolic Protection System
10. Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging
11. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...nhibOx, a leading developer of novel and effective...ned forces with MolPort, an innovator in rare chem...hemical trading platform and builds database of co...s database and its updates to computational chemis...irtual screening procedures. Once they identify su...
(Date:12/4/2009)...st-Selling author and Personal & Organizationa...Transformation through Accountability! , ...4, 2009 -- IMPAQ Accountability Business Consult...est-selling Author, renowned Speaker, and CEO &...ants Inc., will present at the 14th International ...
(Date:12/3/2009)...iropractic Traffic has gotten into the holiday spi...rketing tool. $1 gets chiropractors 3 months of un... Traffic is even including chiropractic promotiona... (PRWEB) December 3, 2009 -- Chiropractic Marke...tool. Chiropractic Marketing expertise provided b...
(Date:12/3/2009)...., Dec. 3 The development of Unive...MCPP) reached a milestone today with a "topping ou... construction at the new hospital that will replac..., (Photo: http://www.newscom.com/cgi-bin/prnh/... a steelworkers, tradition in which a steel beam c...
(Date:12/3/2009)... The American Medical A...tates District Court for the Southern District of ...reviously disclosed $350 million settlement that w...Health Group. ,, The action brought by the AMA,...ouri State Medical Association, along with several...
Breaking Medicine News(10 mins):Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3Health News:Mark Samuel, CEO & Founder, IMPAQ Accountability Business Consultants Inc., to Present at 14th ICF Annual International Conference 2Health News:New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 3Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 4Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2
... 26 days across deserts and mountains, a group of ...oss-country motorbike// expedition to spread aware...ebruary 26 from Bangalore, Karnataka, the group of...in other such expeditions before but they have bee...
...ildhood could fall victims to other types of cance... Early attention and prompt treatment could help...es more likely to develop other types of cancers t...ute lymphoblastic leukemia as children and adolesc...
...ng center and cervical cancer screening program wi...rba Gandhi Hospital// (KGH) at Chennai, capital of... to determine the cause of abnormalities found in ...ican anatomist. It is used to detect changes that ...
...ave demanded a commitment for more funding if talk...nt review of the NHS Wheelchair// and Seating Serv...0m a year. But the Scottish Executive has agreed a... too lightly. Meanwhile BBC Scotland has come to u...
... been established at Kattankulathur, off Chennai, ...//. It will be functioning as part of the SRM Med.... Sathyanarayanan, Vice Chancellor, SRM University... It would commence from the academic year 20...
...tte smoking may actually aid in decreasing the ris...quential association// between smoking and reduced...s conducted by Evan L. Thacker and colleagues from...ibilities of neuro-protective chemicals that may b...
Other Medicine News:Health News:Cross-country Mobike Expedition to Spread AIDS Awareness 2Health News:New School of Public Health in Chennai 2
(Date:12/3/2009)..., , PISCATAWAY, N.J., Dec. 3 /PRNewswir...letin Board: MLSS), the recognized leader in advan...t had entered into a joint venture with China Nati...) and Yichang Humanwell Pharmaceutical Co. Ltd., b... (the "PRC"), to develop orthopedic and epidural d...
(Date:12/3/2009)..., , WALTHAM, Mass., Dec. 3 /PRNewswire...ing research and advisory firms focusing on pharma... type 2 diabetes drug market in Brazil will grow f...The projected 15 percent annual growth rate is att...pulation, increased use of new generation antidiab...
(Date:12/3/2009)..., , SAN DIEGO, Dec. 3 Amir...sitive data from a Phase 1 clinical study of AM461...f the DP2 (also known as CRTH2) receptor. ,, ...tional pharmacodynamic (PD) effect can be achieved...date demonstrates a good safety profile. AM461 is...
Breaking Medicine Technology:Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 2Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 3Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211 2BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program 47480 1BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program 47480 2BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program 47480 3Record 73 4 Million Pounds Collected in Letter Carriers National Food Drive 47476 1Record 73 4 Million Pounds Collected in Letter Carriers National Food Drive 47476 2Kendle Expands Asia Pacific Operations with Opening of Offices in Kuala Lumpur Bangkok and Manila 12390 1Kendle Expands Asia Pacific Operations with Opening of Offices in Kuala Lumpur Bangkok and Manila 12390 2Kendle Expands Asia Pacific Operations with Opening of Offices in Kuala Lumpur Bangkok and Manila 12390 3
...at Tufts Medical Center have created a formula for... certain genetic profiles and lifestyle behaviors ...tion (AMD), a potentially blinding condition that ...mericans and is increasing dramatically as the pop...eddon, MD, ScM, Professor of Ophthalmology at Tuf...
...44th Annual Meeting of EASL , , Management to Dis...nancial Results Call at 5 P.M. EDT Today , , SAN...sdaq: ANDS ) today announced that ANA598, the Co...inhibitor, demonstrated potent antiviral activity ...se Ib study in which patients chronically infected...
Other Medicine Technology:Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD) 2ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 2ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 3ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 4ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 5ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 6ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 7ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 8
... A Test gives your laboratory clear-cut results in...icile, you can't afford to wait. For any laborator...t its suspected C. difficile samples for testing, ...ill cut costs and minimize your time-to-results wh...
Clearview C DIFF A
...ion, accuracy and easy operation TOMEYs patented l...viding high resolution. The laser alignment system... cone design eliminates nose & brow shadow & provi...l of the rings promotes patient comfort. New TMS S...
Pachycam
Medicine Products: